Table 2 Overall AEs in participants ≥60 years of age with ≥5% incidence in any treatment group
AEs, n (%) | Quarterly fremanezumab (n = 74) | Monthly fremanezumab (n = 92) | Placebo (n = 80) |
|---|---|---|---|
Any AE | 48 (65) | 53 (58) | 44 (55) |
SAEs | 2 (3) | 3 (3) | 2 (3) |
AEs leading to discontinuation | 1 (1) | 1 (1) | 2 (3) |
Most common AEs (incidence ≥5% in any treatment group) | |||
Injection-site induration | 11 (15) | 23 (25) | 14 (18) |
Injection-site pain | 13 (18) | 19 (21) | 10 (13) |
Injection-site erythema | 8 (11) | 10 (11) | 13 (16) |
Nasopharyngitis | 4 (5) | 5 (5) | 4 (5) |